Loading...

Solasia Pharma K.K

DB:9SO
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
9SO
DB
¥20B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Solasia Pharma K.K. operates as a pharmaceutical company in Asia. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
  • Solasia Pharma K.K has significant price volatility in the past 3 months.
9SO Share Price and Events
7 Day Returns
1.5%
DB:9SO
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-38.8%
DB:9SO
-9.2%
DE Biotechs
-6.7%
DE Market
9SO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Solasia Pharma K.K (9SO) 1.5% -13.7% 10.1% -38.8% - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 9SO underperformed the Biotechs industry which returned -9.2% over the past year.
  • 9SO underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
9SO
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Solasia Pharma K.K's competitors could be found in our database.

Value

 Is Solasia Pharma K.K undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Solasia Pharma K.K. This is due to cash flow or dividend data being unavailable. The share price is €1.476.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Solasia Pharma K.K's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Solasia Pharma K.K's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:9SO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥-25.98
TSE:4597 Share Price ** TSE (2019-04-18) in JPY ¥188
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Solasia Pharma K.K.

DB:9SO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4597 Share Price ÷ EPS (both in JPY)

= 188 ÷ -25.98

-7.24x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Solasia Pharma K.K is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Solasia Pharma K.K is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Solasia Pharma K.K's expected growth come at a high price?
Raw Data
DB:9SO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.24x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Solasia Pharma K.K, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Solasia Pharma K.K's assets?
Raw Data
DB:9SO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥67.69
TSE:4597 Share Price * TSE (2019-04-18) in JPY ¥188
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:9SO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4597 Share Price ÷ Book Value per Share (both in JPY)

= 188 ÷ 67.69

2.78x

* Primary Listing of Solasia Pharma K.K.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Solasia Pharma K.K is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Solasia Pharma K.K's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Solasia Pharma K.K has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Solasia Pharma K.K expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Solasia Pharma K.K has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Solasia Pharma K.K expected to grow at an attractive rate?
  • Unable to compare Solasia Pharma K.K's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Solasia Pharma K.K's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Solasia Pharma K.K's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:9SO Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:9SO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:9SO Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:9SO Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 318 -2,323 -2,422
2018-09-30 111 -2,238 -2,129
2018-06-30 489 -1,440 -1,378
2018-03-31 414 -1,169 -1,086
2017-12-31 410 -911 -1,007
2017-09-30 709 -493
2016-12-31 501 -464 -762

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Solasia Pharma K.K is high growth as no earnings estimate data is available.
  • Unable to determine if Solasia Pharma K.K is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:9SO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Solasia Pharma K.K Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9SO Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:9SO Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 -25.98
2018-09-30 -23.92
2018-06-30 -15.67
2018-03-31 -12.39
2017-12-31 -12.24
2017-09-30 -6.80
2016-12-31 -18.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Solasia Pharma K.K will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Solasia Pharma K.K's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Solasia Pharma K.K's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Solasia Pharma K.K's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Solasia Pharma K.K's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Solasia Pharma K.K has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Solasia Pharma K.K performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Solasia Pharma K.K's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Solasia Pharma K.K does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Solasia Pharma K.K's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Solasia Pharma K.K's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Solasia Pharma K.K's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Solasia Pharma K.K Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9SO Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 318.00 -2,422.00 1,061.00 1,463.00
2018-09-30 111.00 -2,129.00 888.00 1,275.00
2018-06-30 489.00 -1,378.00 827.00 971.00
2018-03-31 414.00 -1,086.00 701.00 798.00
2017-12-31 410.00 -1,007.00 647.00 773.00
2017-09-30 709.00 -492.53 628.00 512.00
2016-12-31 501.00 -761.71 488.00 475.00
2015-12-31 229.00 -916.64 458.00 473.00
2014-12-31 11.00 -677.00 476.00 237.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Solasia Pharma K.K has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Solasia Pharma K.K has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Solasia Pharma K.K improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Solasia Pharma K.K's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Solasia Pharma K.K has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Solasia Pharma K.K's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Solasia Pharma K.K's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Solasia Pharma K.K is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Solasia Pharma K.K's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Solasia Pharma K.K's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Solasia Pharma K.K has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Solasia Pharma K.K Company Filings, last reported 3 months ago.

DB:9SO Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 7,087.00 0.00 4,046.00
2018-09-30 7,975.00 0.00 4,647.00
2018-06-30 5,303.00 0.00 2,070.00
2018-03-31 5,892.00 0.00 2,772.00
2017-12-31 6,208.00 0.00 3,370.00
2017-09-30 6,804.00 0.00 3,897.00
2016-12-31 3,433.00 0.00 1,038.00
2015-12-31 998.00 2,867.00 2,099.00
2014-12-31 253.00 1,321.00 501.00
  • Solasia Pharma K.K has no debt.
  • Solasia Pharma K.K currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Solasia Pharma K.K has sufficient cash runway for 1.6 years based on current free cash flow.
  • Solasia Pharma K.K has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 44.4% each year.
X
Financial health checks
We assess Solasia Pharma K.K's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Solasia Pharma K.K has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Solasia Pharma K.K's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Solasia Pharma K.K dividends.
If you bought €2,000 of Solasia Pharma K.K shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Solasia Pharma K.K's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Solasia Pharma K.K's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:9SO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:9SO Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Solasia Pharma K.K has not reported any payouts.
  • Unable to verify if Solasia Pharma K.K's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Solasia Pharma K.K's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Solasia Pharma K.K has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Solasia Pharma K.K's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Solasia Pharma K.K afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Solasia Pharma K.K has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Solasia Pharma K.K's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yoshihiro Arai
AGE 58
TENURE AS CEO 6.2 years
CEO Bio

Mr. Yoshihiro Arai has been the President and Representative Director at Solasia Pharma KK since February 2013. Mr. Arai served as Executive Vice President of Development of JapanBridge, Inc. since September 2007. Mr. Arai served as Executive Vice President of Development of Solasia Pharma, K.K. He joined Solasia in September 2007 with responsibility for all product development including clinical development and regulatory affairs. Prior to joining Solasia, he spent 14 years at Amgen K.K. from initial stage of it where he led development of Amgen's novel hematology/oncology products, built the Clinical Development Division and held numerous senior level positions. Prior to joining Amgen, Mr. Arai spent 9 years at Searle Yakuhin where he developed gastro intestinal, psychiatric and oncology product. He earned a B.S degree and a Master degree in Biochemistry & Microbiology from Tokyo University of Pharmacy and a M.B.A. from the University of Wales.

CEO Compensation
  • Insufficient data for Yoshihiro to compare compensation growth.
  • Insufficient data for Yoshihiro to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Yoshihiro Arai

TITLE
President and Representative Director
AGE
58
TENURE
6.2 yrs

Toshio Miyashita

TITLE
Chief Financial Officer
AGE
51

Koji Shinozaki

TITLE
Head of Business Development Department

Shigeru Sakamaki

TITLE
Head of Product Development Division
Board of Directors Tenure

Average tenure and age of the Solasia Pharma K.K board of directors in years:

3.3
Average Tenure
64
Average Age
  • The tenure for the Solasia Pharma K.K board of directors is about average.
Board of Directors

Toshio Miyashita

TITLE
Chief Financial Officer
AGE
51
TENURE
3.3 yrs

Masahiro Michisuji

TITLE
External Director
AGE
83
TENURE
10.9 yrs

Yoshihiro Arai

TITLE
President and Representative Director
AGE
58
TENURE
6.2 yrs

Yasuhiro Abe

TITLE
External Director
AGE
50

Stanley Lau

TITLE
External Director
AGE
64

Norikazu Eiki

TITLE
External Director
AGE
70
TENURE
2.9 yrs

Koichi Sagiya

TITLE
Full-Time External Corporate Auditor
AGE
78

Makoto Matsuo

TITLE
External Corporate Auditor
AGE
69

Tasuku Toita

TITLE
External Corporate Auditor
AGE
41

Susumu Araki

TITLE
Statutory Auditor
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Solasia Pharma K.K's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Solasia Pharma K.K has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Solasia Pharma K.K. operates as a pharmaceutical company in Asia. It offers episil oral liquid for the management of pain and relief of pain; and Sancuso, a transdermal delivery system that delivers the anti-emetic and granisetron into the patient’s bloodstream to patients receiving chemotherapy. The company is also developing SP-02, a mitochondrial-targeted agent, which is in Phase II clinical study to treat various hematologic and solid cancers; and SP-04, which has completed phase IIb clinical trial for chemotherapy induced peripheral neuropathy. The company was founded in 2006 and is based in Tokyo, Japan.

Details
Name: Solasia Pharma K.K.
9SO
Exchange: DB
Founded: 2006
¥156,861,864
104,971,753
Website: http://www.solasia.co.jp
Address: Solasia Pharma K.K.
Sumitomo Fudosan Shiba-Koen Tower,
4th Floor,
Tokyo,
105-0011,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4597 Common Shares The Tokyo Stock Exchange JP JPY 24. Mar 2017
DB 9SO Common Shares Deutsche Boerse AG DE EUR 24. Mar 2017
Number of employees
Current staff
Staff numbers
31
Solasia Pharma K.K employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:32
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/13
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.